…
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Phreesia provides patient intake and revenue-cycle management software that automates check-in, insurance capture, payments and related workflows for ambulatory and outpatient providers. Long-term growth may be driven by ongoing healthcare digitization, expansion of payment and RCM services, and deeper integration with electronic health record systems. Investors may find the recurring SaaS model, an established provider customer base and data-enabled operational efficiencies attractive.
The company faces material risks from competition with EHR vendors and other digital-health firms, sensitivity to provider spending and reimbursement trends, and operational and data-security exposure related to handling protected health information.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Income before tax | -8.94M | -55.81M | -135.34M | -175.66M | -117.98M |
| Net income | 2.31M | -58.53M | -136.88M | -176.15M | -118.16M |
| Selling general administrative | 79.90M | 76.60M | 79.93M | 80.38M | 68.67M |
| Selling and marketing expenses | 100.24M | 121.13M | 147.01M | 151.26M | 106.42M |
| Gross profit | 326.47M | 284.88M | 232.29M | 171.64M | 131.84M |
| Reconciled depreciation | 31.45M | 27.89M | 29.49M | 25.30M | 21.30M |
| Ebit | -1.99M | -53.46M | -133.49M | -176.55M | -116.82M |
| Ebitda | 29.47M | -25.58M | -102.94M | -151.25M | -95.52M |
| Depreciation and amortization | 31.45M | 27.89M | 30.54M | 25.30M | 21.30M |
| Non operating income net other | - | - | - | -0.17M | - |
| Operating income | -6.61M | -58.10M | -136.48M | -176.55M | -116.82M |
| Other operating expenses | 487.20M | 477.91M | 492.78M | 457.46M | 330.05M |
| Interest expense | 6.95M | 2.35M | 1.85M | 1.41M | 1.16M |
| Tax provision | -11.25M | 2.72M | 1.54M | 0.48M | 0.18M |
| Interest income | 2.17M | 2.68M | 4.07M | 1.06M | 1.08M |
| Net interest income | -4.78M | 0.33M | 2.21M | 1.06M | -1.08M |
| Income tax expense | -11.25M | 2.72M | 1.54M | 0.48M | 0.18M |
| Total revenue | 480.59M | 419.81M | 356.30M | 280.91M | 213.23M |
| Total operating expenses | 333.08M | 342.98M | 368.77M | 348.19M | 248.66M |
| Cost of revenue | 154.12M | 134.93M | 124.01M | 109.27M | 81.39M |
| Total other income expense net | -2.33M | 2.29M | 1.14M | 0.89M | -1.16M |
| Net income from continuing ops | 2.31M | -58.53M | -136.88M | -176.15M | -118.16M |
| Net income applicable to common shares | 2.31M | -58.53M | -136.88M | -176.15M | -118.16M |
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Total assets | 663.79M | 388.42M | 370.33M | 370.06M | 494.48M |
| Intangible assets | 79.76M | 80.91M | 77.76M | 46.55M | 30.41M |
| Other current assets | 51.39M | 45.45M | 42.53M | 33.31M | 30.63M |
| Total liab | 326.58M | 123.61M | 118.88M | 82.24M | 77.20M |
| Total stockholder equity | 337.21M | 264.81M | 251.45M | 287.82M | 417.28M |
| Deferred long term liab | - | - | - | 2.68M | 3.75M |
| Other current liab | 113.02M | 64.13M | 68.03M | 44.41M | 39.72M |
| Common stock | 0.62M | 0.60M | 0.58M | 0.54M | 0.52M |
| Capital stock | 0.62M | 0.60M | 0.58M | 0.54M | 0.52M |
| Retained earnings | -799.19M | -801.50M | -742.97M | -606.08M | -429.94M |
| Other liab | - | - | - | 0.12M | 0.07M |
| Good will | 170.06M | 75.84M | 75.84M | 33.74M | 33.62M |
| Other assets | 9.79M | 3.25M | 0.00M | 5.09M | 7.11M |
| Cash | 73.83M | 84.22M | 87.52M | 176.68M | 313.81M |
| Cash and equivalents | 73.83M | 84.22M | 87.52M | 176.68M | 313.81M |
| Total current liabilities | 183.24M | 114.02M | 110.12M | 79.04M | 68.43M |
| Current deferred revenue | 49.52M | 32.76M | 24.11M | 17.69M | 16.49M |
| Net debt | 28.62M | -66.42M | -75.54M | -167.50M | -298.01M |
| Short term debt | 9.22M | 9.01M | 6.45M | 6.11M | 7.10M |
| Short long term debt | 2.66M | 1.22M | 1.10M | 5.17M | 5.82M |
| Short long term debt total | 102.45M | 17.80M | 11.98M | 9.18M | 15.80M |
| Other stockholder equity | 1136.16M | 1065.75M | 993.84M | 893.36M | 846.70M |
| Property plant equipment | 22.33M | 25.13M | 17.17M | 22.24M | 36.98M |
| Total current assets | 279.84M | 203.28M | 195.68M | 262.44M | 386.35M |
| Net tangible assets | - | - | - | 254.08M | 353.24M |
| Net receivables | 154.63M | 73.62M | 64.86M | 51.39M | 40.26M |
| Long term debt | 90.00M | 0.72M | 2.05M | 2.73M | 0.14M |
| Inventory | - | - | 0.77M | 1.06M | 1.64M |
| Accounts payable | 11.48M | 5.62M | 8.48M | 10.84M | 5.12M |
| Accumulated other comprehensive income | -0.38M | -0.05M | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.54M | - |
| Retained earnings total equity | - | - | - | -606.08M | - |
| Treasury stock | - | - | - | -33.60M | -13.96M |
| Non currrent assets other | 55.80M | 3.25M | 3.87M | 5.01M | 6.59M |
| Non current assets total | 383.95M | 185.13M | 174.64M | 107.62M | 108.13M |
| Capital lease obligations | 9.79M | 15.87M | 8.84M | 1.28M | 15.80M |
| Long term debt total | 92.12M | 8.15M | 5.40M | 2.73M | 7.42M |
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Investments | - | -24.09M | -39.67M | -26.20M | -65.23M |
| Change to liabilities | - | - | - | 7.49M | 6.23M |
| Total cashflows from investing activities | -161.88M | -24.09M | -39.67M | -26.20M | -65.23M |
| Net borrowings | 83.17M | -7.81M | -6.78M | -0.61M | -5.31M |
| Total cash from financing activities | 72.85M | -11.49M | -17.11M | -20.80M | 234.97M |
| Change to operating activities | - | - | - | 1.24M | -14.58M |
| Net income | 2.31M | -58.53M | -136.88M | -176.15M | -118.16M |
| Change in cash | -10.39M | -3.30M | -89.16M | -137.13M | 95.03M |
| Begin period cash flow | 84.22M | 87.52M | 176.68M | 313.81M | 218.78M |
| End period cash flow | 73.83M | 84.22M | 87.52M | 176.68M | 313.81M |
| Total cash from operating activities | 78.81M | 32.38M | -32.38M | -90.12M | -74.71M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 245.81M |
| Depreciation | 31.45M | 27.89M | 29.49M | 25.30M | 21.30M |
| Other cashflows from investing activities | -13.30M | -15.38M | -19.29M | -21.47M | -34.42M |
| Dividends paid | - | - | 12.18M | - | 0.00M |
| Change to account receivables | -10.15M | -8.81M | -11.21M | -11.13M | -10.22M |
| Sale purchase of stock | 1.45M | 1.01M | -12.18M | -19.38M | -8.99M |
| Other cashflows from financing activities | -14.15M | -7.61M | 1.84M | 2.71M | 2.42M |
| Change to netincome | - | - | - | 59.21M | 38.22M |
| Capital expenditures | 11.10M | 24.09M | 25.10M | 26.20M | 30.80M |
| Change receivables | - | - | - | -11.13M | - |
| Cash flows other operating | - | - | - | 4.84M | - |
| Cash and cash equivalents changes | - | - | - | -137.13M | - |
| Change in working capital | -14.09M | -6.49M | -1.64M | -3.86M | -18.57M |
| Stock based compensation | 67.45M | 66.97M | 71.70M | 58.77M | 36.14M |
| Other non cash items | 4.96M | 2.33M | 4.73M | 5.37M | 4.43M |
| Free cash flow | 67.71M | 8.29M | -57.48M | -116.33M | -105.52M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PHR Phreesia Inc |
-0.45 3.79% |
11.42 | 57.50 | 12.80 | 1.27 | 1.72 | 1.25 | 12.69 |
| VEEV Veeva Systems Inc Class A |
-0.05 0.02% |
266.22 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
-6.60 5.03% |
124.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-5.60 9.39% |
54.01 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.31% |
5.28 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
| Name | Title | Year Born |
|---|---|---|
| Mr. Chaim Indig | Co-Founder, CEO & Director | 1979 |
| Mr. Evan Roberts | Co-Founder & COO | 1980 |
| Mr. Randy Rasmussen | Chief Financial Officer | 1980 |
| Ms. Allison C. Hoffman | Gen. Counsel & Sec. | 1971 |
| Mr. David Linetsky | Sr. VP of Life Sciences | 1979 |
| Mr. Daniel Nathan | Chief Technology Officer | 1977 |
| Mr. Balaji Gandhi | Sr. VP of Investor Relations | NA |
| Ms. Maureen McKinney | VP of Corp. Communications | NA |
| Ms. Amy Beth VanDuyn | Sr. VP of HR | 1974 |
| Mr. Michael J. Davidoff | Sr. VP of Payer Solutions | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.